183 filings
Page 5 of 10
10-Q
2022 Q1
IKT
Inhibikase Therapeutics Inc
Quarterly report
16 May 22
12:00am
DEFA14A
IKT
Inhibikase Therapeutics Inc
3 May 22
Additional proxy soliciting materials
10:33am
DEF 14A
IKT
Inhibikase Therapeutics Inc
Definitive proxy
2 May 22
5:06pm
PRE 14A
IKT
Inhibikase Therapeutics Inc
21 Apr 22
Preliminary proxy
4:33pm
8-K
IKT
Inhibikase Therapeutics Inc
21 Apr 22
Regulation FD Disclosure
4:19pm
10-K
2021 FY
IKT
Inhibikase Therapeutics Inc
Annual report
31 Mar 22
4:12pm
8-K
IKT
Inhibikase Therapeutics Inc
24 Mar 22
Regulation FD Disclosure
9:17am
8-K/A
IKT
Inhibikase Therapeutics Inc
21 Mar 22
Departure of Directors or Certain Officers
4:30pm
4
IKT
Inhibikase Therapeutics Inc
21 Mar 22
Inhibikase Therapeutics / JOSEPH FRATTAROLI ownership change
4:05pm
4
Milton H. Werner
21 Mar 22
Inhibikase Therapeutics / Milton H. Werner ownership change
4:05pm
4
IKT
Inhibikase Therapeutics Inc
9 Mar 22
Inhibikase Therapeutics / JOSEPH FRATTAROLI ownership change
8:22pm
4
IKT
Inhibikase Therapeutics Inc
9 Mar 22
Inhibikase Therapeutics / Milton H. Werner ownership change
8:21pm
8-K
IKT
Inhibikase Therapeutics Inc
8 Mar 22
Departure of Directors or Certain Officers
4:38pm
EFFECT
IKT
Inhibikase Therapeutics Inc
14 Feb 22
Notice of effectiveness
12:15am
SC 13G/A
IKT
Inhibikase Therapeutics Inc
11 Feb 22
Inhibikase Therapeutics / Werner Milton H. ownership change
5:15pm
CORRESP
IKT
Inhibikase Therapeutics Inc
9 Feb 22
Correspondence with SEC
12:00am
UPLOAD
IKT
Inhibikase Therapeutics Inc
9 Feb 22
Letter from SEC
12:00am
S-3
IKT
Inhibikase Therapeutics Inc
7 Feb 22
Shelf registration
12:00am
8-K
IKT
Inhibikase Therapeutics Inc
20 Jan 22
Clinical Development of Therapies Intended to Reverse the Functional Loss in Parkinson’s and Related Disorders 1Q 2022 BUSINESS PRESENTATION IKT
4:10pm
SC 13D
FiveT Investment Management Ltd
11 Jan 22
Inhibikase Therapeutics / FiveT Investment Management ownership change
12:04pm